Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Hua Medicine (Shanghai) Ltd. is managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners, but they are concentrated within only 2 distinct art units. MCDOWELL, BRIAN E is the busiest examiner, holding 1 pending action. The concentration of 3 actions within 2 art units suggests that the company's technology is being reviewed within a narrow administrative scope, even as multiple examiners are involved.
From a prosecution standpoint, having 3 pending office actions reviewed by 3 distinct examiners means that the practitioner must address different examination styles. However, the limitation to 2 distinct art units provides a more focused environment. MCDOWELL, BRIAN E, the busiest examiner with 1 pending action, has a workload equal to the other examiners. Because the 3 actions are spread across only 2 art units, at least one art unit is overseeing multiple cases. This can be beneficial for identifying consistent patterns in how the Biotechnology & Pharmaceuticals claims are being treated within those specific units. The practitioner must coordinate responses that are mindful of the 2 distinct art units while addressing the individual concerns of the 3 distinct examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.0% |
| CHI, AMANDA LYNN | 1 | — | — |
| MURESAN, ANA Z | 1 | 75.0% | +31.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042901 | PREPARATION OF SUBSTITUTED ACRYLATE COMPOUND | MURESAN, ANA Z | 56d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042901 | PREPARATION OF SUBSTITUTED ACRYLATE COMPOUND | MURESAN, ANA Z | 56d overdue |
| 18746554 | PRODRUG OF PYRROLIDONE DERIVATIVES AS GLUCOKINASE ACTIVATOR | MCDOWELL, BRIAN E | — |
| Art Unit | Apps |
|---|---|
| 1600 | 1 |
| 1692 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18746554 | PRODRUG OF PYRROLIDONE DERIVATIVES AS GLUCOKINASE ACTIVATOR | MCDOWELL, BRIAN E | — | §112 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18610100 | PHARMACEUTICAL COMBINATION, COMPOSITION AND COMPOUND PREPARATION COMPRISING GLUCOKINASE ACTIVATOR AND DPP-IV INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | CHI, AMANDA LYNN | 1600 | §103Other | Final Rejection | — | Pending | Mar 19, 2024 |
| 18042901 | PREPARATION OF SUBSTITUTED ACRYLATE COMPOUND | MURESAN, ANA Z | 1692 | §102§112 | Non-Final OA | 56d overdue | Pending | Feb 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHua Medicine (Shanghai) Ltd. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Brian E Mcdowell has the most, with 1 of Hua Medicine (Shanghai) Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
